| 1 |
Semo D, Obergassel J, Dorenkamp M, Hemling P, Strutz J, Hiden U, Müller N, Müller UA, Zulfikar SA, Godfrey R, Waltenberger J. The Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Empagliflozin Reverses Hyperglycemia-Induced Monocyte and Endothelial Dysfunction Primarily through Glucose Transport-Independent but Redox-Dependent Mechanisms. J Clin Med 2023;12. [PMID: 36835891 DOI: 10.3390/jcm12041356] [Reference Citation Analysis]
|
| 2 |
Jankauskas SS, Kansakar U, Sardu C, Varzideh F, Avvisato R, Wang X, Matarese A, Marfella R, Ziosi M, Gambardella J, Santulli G. COVID-19 Causes Ferroptosis and Oxidative Stress in Human Endothelial Cells. Antioxidants (Basel) 2023;12. [PMID: 36829885 DOI: 10.3390/antiox12020326] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
|
| 3 |
Avvisato R, Jankauskas SS, Santulli G. Istaroxime and Beyond: New Therapeutic Strategies to Specifically Activate SERCA and Treat Heart Failure. J Pharmacol Exp Ther 2023;384:227-30. [PMID: 36581352 DOI: 10.1124/jpet.122.001446] [Reference Citation Analysis]
|
| 4 |
Gambardella J, Fiordelisi A, Sorriento D, Cerasuolo F, Buonaiuto A, Avvisato R, Pisani A, Varzideh F, Riccio E, Santulli G, Iaccarino G. Mitochondrial microRNAs Are Dysregulated in Patients with Fabry Disease. J Pharmacol Exp Ther 2023;384:72-8. [PMID: 35764328 DOI: 10.1124/jpet.122.001250] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 5 |
Santulli G. Non-Coding RNAs in Clinical Practice: From Biomarkers to Therapeutic Tools. J Pharmacol Exp Ther 2023;384:225-6. [PMID: 36581351 DOI: 10.1124/jpet.122.001457] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 6 |
La Grotta R, Frigé C, Matacchione G, Olivieri F, de Candia P, Ceriello A, Prattichizzo F. Repurposing SGLT-2 Inhibitors to Target Aging: Available Evidence and Molecular Mechanisms. Int J Mol Sci 2022;23:12325. [PMID: 36293181 DOI: 10.3390/ijms232012325] [Reference Citation Analysis]
|
| 7 |
Santulli G, Frullone S, Morgante M, Macina G, Pansini A, Gambardella J, Lombardi A, Mone P. Response to Comment on Mone et al. Empagliflozin Improves Cognitive Impairment in Frail Older Adults With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction. Diabetes Care 2022;45:1247-1251. Diabetes Care 2022;45:e151-2. [PMID: 36150055 DOI: 10.2337/dci22-0025] [Reference Citation Analysis]
|
| 8 |
Gliozzi M, Macrì R, Coppoletta AR, Musolino V, Carresi C, Scicchitano M, Bosco F, Guarnieri L, Cardamone A, Ruga S, Scarano F, Nucera S, Mollace R, Bava I, Caminiti R, Serra M, Maiuolo J, Palma E, Mollace V. From Diabetes Care to Heart Failure Management: A Potential Therapeutic Approach Combining SGLT2 Inhibitors and Plant Extracts. Nutrients 2022;14:3737. [PMID: 36145112 DOI: 10.3390/nu14183737] [Reference Citation Analysis]
|
| 9 |
Jiang Y, Xie J. Cost-effectiveness of adding empagliflozin to the standard therapy for Heart Failure with Preserved Ejection Fraction from the perspective of healthcare systems in China. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.946399] [Reference Citation Analysis]
|
| 10 |
Deng R, Jiang K, Chen F, Miao Y, Lu Y, Su F, Liang J, Qian J, Wang D, Xiang Y, Shen L. Novel cardioprotective mechanism for Empagliflozin in nondiabetic myocardial infarction with acute hyperglycemia. Biomed Pharmacother 2022;154:113606. [PMID: 36030589 DOI: 10.1016/j.biopha.2022.113606] [Reference Citation Analysis]
|
| 11 |
Pasquale Mone, Antonio de Donato, Fahimeh Varzideh, Urna Kansakar, Stanislovas S. Jankauskas, Antonella Pansini, Gaetano Santulli. Functional role of miR-34a in diabetes and frailty. Front Aging 2022;3:949924. [PMID: 35923683 DOI: 10.3389/fragi.2022.949924] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
